Potential uses of cytisine for smoking cessation in menopausal women – literature summary
Metadatos
Mostrar el registro completo del ítemEditorial
Group Publishing, Inc.
Materia
Cytisine Smoking cessation Menopause Nicotine
Fecha
2023Referencia bibliográfica
Rubio, F., Martínez, F. M., & Zarzuelo Romero, M. (2023). Potential uses of cytisine for smoking cessation in menopausal women – literature summary. Menopause Review/Przegląd Menopauzalny, 22(1), 42-48. [https://doi.org/10.5114/pm.2023.126439]
Resumen
Introduction: Menopause is a vital stage in which the risk of the appearance of metabolic syndrome and
cardiovascular diseases is increased. Cardiovascular risk in menopausal women must be monitored because it is
one of the most common causes of mortality in these women. Smoking is an important risk factor for the development
of many diseases, including cardiovascular diseases, so promoting smoking cessation in these women
is important for the maintenance of cardiovascular health.
Material and methods: Current smoking cessation programs mainly include nicotine and varenicline as
therapeutic agents, due to their history of success, safety, and efficacy in aiding in cessation, but they do not
include “new” agents such as cytisine as coadjuvant in the elimination of the habit of smoking.
Results: Cytisine is a therapeutic agent traditionally used in Eastern Europe, which has demonstrated efficacy
and safety in smoking cessation, also showing other new pharmacological actions. It has been widely used
since World War II as a nicotine substitute.
Conclusions: These pharmacological actions, together with their efficacy in smoking cessation, should be
explored to evaluate the convenience of the use of cytisine in premenopausal and postmenopausal women,
so that cytisine can be identified as a useful therapeutic tool in smoking cessation programs and in particular
in menopausal women.